ExpressDetect® Mitch Sanders, CEO

June 2009 ECI Biotech  ECI Biotech is a premier developer of ExpressDetect® Diagnostics.  ExpressDetect ® Diagnostics are simple, inexpensive, rapid, and safe.  ECI has development agreements with industry leaders in Consumer and Professional Health Care.  ECI Biotech has secured an aggregate of $18M in development funding, grants, and private equity.

June 2009 Funding History  Equity Financing$7.5 M Collaborative Seed and Growth Partners, LLC Vik Brothers International The GS Fuller Foundation  Corporate Development Funding$5.0 M  GrantsPhase I and II SBIR$1.9 M

June 2009  Corporate Development Funding  Current $1M  SBIR Grants ProjectAwarded Yeast Diagnostic$200,870 PoC Wound Diagnostic, Phase I$208,311 Therapeutic Agent for Periodontal Disease, years 1+2$242,072 PoC Wound Diagnostic, Phase II$949,000 ProjectPending Detecting Trauma Induced Wound Infections $689,000 Yeast Diagnostic Phase II$1,000,000 Theranostic Grant $269,000

June 2009 A series of high impact, low-cost, fast turnaround assays ExpressDetect ® Technology Summary  Wound Care  Oral Care  Women’s Care  UTI

June 2009 Primary Markets $2.9 B Wound Care Market 9.2% (CAGR) 1. PoC for Clinics & Hospitals 2. Dressing sensor (Home health, VA, and nursing homes) 3. Consumer Band aids 4. Military Product for Combat Casualty Care $2.9 B Oral Care Market (Cleaners/Whiteners/Dentures) 4.9% (CAGR) 1. Consumer Strep Diagnostic 2. Consumer and Professional Gingivitis 3. Consumer and Professional Periodontitis  Partner

June 2009 Secondary Markets $1 B Women’s Health 16.6% (CAGR) 1. Yeast Diagnostic 2. BV-Tric-Yeast Consumer and Professional Care $3 B UTI Diagnostic 40% (CAGR) 1. Consumer UTI 2. Foley Catheter Market  Partner

June 2009 reporter molecules anchor peptide substrate Diagnostic Assay Formats  Peptide covalently attached to microbead anchor and reporter molecule PRESENT ABSENT PATCH PoC

June 2009 ExpressDetect ® Assay Technology InteractionSeparationDetection dual affinity tag peptide bead minutes

June 2009  Advanced Wound Care is a $2.8 B Industry  14M Chronic Wounds Treated Annually  Each patient is checked 8-10 x for infection  Market Opportunity ($840M)  Additional Market (50M Acute Wounds) Biopsy Visual exam only Swab 35% 53% 12%

June 2009  Wounds need to be tested for bacterial load before treatment  Visual Assessment Methods Inaccurate  Current methods take 2-3 days to get results

June 2009  Our test takes 10 minutes  Low cost $16 (vs. $75 swab or $225 biopsy), simple, and safe  Next steps, pre IDE meeting, clinical studies, and launch

June 2009 Time Course of Color Reaction Dressing Sensor Time Course with A. baumannii. In the presence of culture media (BHI) or BHI + A. baumannii incubated for 0, 20, 40, or 60 minutes. Blue color indicates the presence of the pathogen. Scale Bar = 4 cm.

June 2009  Inexpensive (COGS<3 cents), and safe enough for band-aids  Sensor turns blue when infection is likely

June 2009  Detection of Common Wound Pathogens  Threshold is > 10 6 CFU/mL

June 2009  Strong IP with 18 patent families issuing world-wide  Additional design patents in preparation (See IP doc)

June 2009  Clear regulatory path with FDA  Time for Pre-IDE meetings

June 2009 ExpressDetect ® Antibody Visual Signs Culture Real Time    X Specificity   X  Low Cost $16$16+  $75-$225 Broad Spectrum  X   Active Detection  X ? 

June 2009 Chronic Wound Opportunity for ECI = $840 Million  14M wounds; 4 tests/wound; $15/test Revenue (000) ,453 12,691 23,859 EBITDA (1,049) (2,056) (1,412) 4,474 12,339 Pretax/Net Income (1,223) (2,693) (1,706) 4,015 9,146

June 2009 $3M $2M $3M $2M Manufacturing

June 2009 ECI Organization Chart

June 2009  ExpressDetect ® - simple, inexpensive, rapid, & safe  Large Markets ($BB)  Primary Products in Wound Care  Pipeline (oral care, women’s health, & UTI)  Significant revenue >$50M and liquidity opportunity